Welcome to our dedicated page for Kala Pharmaceuticals SEC filings (Ticker: KALA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Clinical-stage biotech filings can feel impenetrable—especially when they involve stem-cell secretomes, nanoparticle delivery science, and pages of trial data. Kala Pharmaceuticals SEC filings explained simply is exactly what most investors need when the latest 300-page document lands on EDGAR. Whether you are hunting for safety signals around KPI-012 or trying to gauge cash runway before the next Phase 2 read-out, our AI breaks down the jargon and highlights what really moves the share price.
Here you will find every form, from a Kala Pharmaceuticals annual report 10-K simplified to a Kala Pharmaceuticals quarterly earnings report 10-Q filing, plus Kala Pharmaceuticals 8-K material events explained within minutes of posting. Stock Titan’s AI-powered summaries show where milestone payments hit the income statement, flag trial-halt clauses hidden in footnotes, and answer real questions like “understanding Kala Pharmaceuticals SEC documents with AI” or “Kala Pharmaceuticals earnings report filing analysis” without scrolling line-by-line.
Need real-time visibility into management’s moves? Monitor Kala Pharmaceuticals insider trading Form 4 transactions and receive Kala Pharmaceuticals Form 4 insider transactions real-time alerts that spotlight option exercises and open-market buys. The page also connects each Kala Pharmaceuticals proxy statement executive compensation detail to dilution scenarios so you can calculate true cost of equity. Use our platform to track Kala Pharmaceuticals executive stock transactions Form 4, compare R&D trends across quarters, and export risk-factor lists for your model. Complex filings, clear insights—so you invest with confidence.
Baker Bros. Advisors LP and affiliated filers report beneficial ownership of 744,759 shares of KALA BIO, Inc. common stock, representing 9.99% of the outstanding shares based on a 7,021,040 share base as of August 7, 2025 plus convertible preferred shares. The holdings include 434,200 shares issuable upon conversion of 4,342 Series E preferred shares; conversion of convertible preferred is subject to a 9.99% beneficial ownership limitation (increaseable to 19.99% with 61 days' notice). The filers state the securities are held in the ordinary course of business and not for the purpose of changing or influencing control; prior nomination rights under a purchase agreement were reported as no longer held as of October 2, 2025.
Baker Bros. reporting persons filed a Form 4 disclosing multiple sales of KALA BIO, Inc. (KALA) common stock on 09/30/2025 and 10/01/2025. The filing shows four separate dispositions: 21,376 and 195,425 shares on 09/30/2025 at a weighted average price of $1.5959, and 50,640 and 462,967 shares on 10/01/2025 at a weighted average price of $1.3838. After each reported transaction, the filings list the number of shares beneficially owned by the reporting entities and individuals on an indirect basis. Footnotes state the trading occurred through the Funds (667, L.P. and Baker Brothers Life Sciences, L.P.) across price ranges of $1.50–$1.84 and $1.27–$1.48, and clarify the Adviser and certain partners disclaim beneficial ownership except for pecuniary interest.
KALA BIO, Inc. Schedule 13G reports that Point72-related filers — Point72 Asset Management, Point72 Capital Advisors, Inc., and Steven A. Cohen — jointly disclose beneficial ownership of 469,229 shares of KALA common stock, representing 6.7% of the class as of the close of business on September 10, 2025. The filing states Point72 Asset Management and Point72 Capital Advisors exercise shared voting and dispositive power over these shares through Point72 Associates, an investment fund they manage. The filing includes a Joint Filing Agreement (Exhibit 99.1) and affirms the shares were not acquired to influence control of the issuer.
Perceptive Advisors and related parties report holding 543,745 shares of KALA BIO, Inc., representing 7.7% of the outstanding common stock. The Schedule 13G shows the Master Fund directly holds the shares and that Perceptive Advisors (as investment manager) and Joseph Edelman (managing member) may be deemed to beneficially own those shares. The filing states the position is held passively and not for the purpose of changing or influencing control of the issuer.
KALA BIO, Inc. reporting person Todd Bazemore, identified as a director and officer (President and Chief Executive Officer), was granted a stock option on 08/29/2025 to purchase 180,000 shares of common stock at an exercise price of $11.22 per share. The option vests over four years beginning on the vesting commencement date of 08/29/2025, with 1/48th of the shares vesting at the end of each successive one-month period until 08/29/2029, subject to continued service. The option lists an expiration/exercisable date of 08/28/2035. The Form 4 was signed by an attorney-in-fact on behalf of the reporting person on 09/02/2025.
FAQ
What is the current stock price of Kala Pharmaceuticals (KALA)?
What is the market cap of Kala Pharmaceuticals (KALA)?
